Oracle Report on CELZ .......
Post# of 350
(Total Views: 539)
Posted On: 05/01/2018 12:05:05 AM
Creative Medical Technology Holdings Inc (OTCMKTS:CELZ) is Steamrolling the Bears
By Gene Daniel - April 30, 2018
SHARE Facebook Twitter
Creative Medical Technology Holdings Inc (OTCMKTS:CELZ) continues a resurgence that has seen it jump up over +160% over the last month. In addition, CELZ has seen 10-day volume average 91.46M, so investor interest is very strong here. The recent shareholder update has added some upward action to this price increase. One important point that seemed to interest investors was the paying down of debt. This is not anything new as CELZ has been working to tighten up this aspect of the company while letting their technology get further down the pipeline.
“We continue to focus on the business at hand and our portfolio including issued patents for the treatment of erectile dysfunction, degenerative disc disease and our amniotic derived stem cell as well as patents pending in the area of neurological damage due to radiation toxicity and stroke amongst others,” said Timothy Warbington, CEO of CELZ.
Creative Medical Technology Holdings Inc (OTCMKTS:CELZ) bills itself as a company that is engaged in stem cell research and applications for use to treat male and female sexual dysfunction, infertility and related issues. It holds a patent for its erectile dysfunction (“ED”) treatment and was granted a license by Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, a non-profit biomedical research and education institute (“LABIOMED”), for the infertility treatment.
It has also filed a patent application focused on physical manifestations of female sexual arousal disorder, as an extension of the work with stem cell therapies for ED. Following testing of its ED treatment, Creative Medical intends to market treatment kits to physicians for use with their patients suffering from ED. During first quarter 2016, it commenced a 15-month clinical trial study being conducted at UCLA by LABIOMED on the efficacy and safety of the ED treatment.
The study involves testing on 40 subjects. Following further testing, Creative Medical also intends to market licensed products under its infertility technology license and the female sexual dysfunction patent application.
According to company materials, “Creative Medical Technology Holdings, Inc. is a clinical-stage biotechnology company currently trading on the OTCQB under the ticker symbol CELZ.”
Find out when $CELZ stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
Speaking of CELZ’s technology, let’s take a look at that more closely. CELZ’s CaverStem procedure is seeing an opportunity in the urology market for a subset of the male population that does not react to Viagra or Cialis. This subset is not small – 30 million men are resistant to the two well known erectile dysfunction options.
Furthermore, the company has a new subsidiary called CerebroStemLLC working to treat brain injuries through stem cell therapy through their product AmnioStem. “We are extremely excited about our data, which positions Creative Medical Technology Holdings as a force in the autoimmune market. In addition to treatment of stroke and radiation toxicity, autoimmune diseases that may benefit from use of AmnioStem™ technology include Type 1 Diabetes, Rheumatoid Arthritis, Multiple Sclerosis, and Lupus,” said Timothy Warbington, President and Chief Executive Officer of Creative Medical Technology Holdings. “I am thankful for our collaborative network of scientists, scientific advisors, and intellectual property advisors, which are currently working in expanding the intellectual property portfolio surrounding this new cell type.”
CELZ has put solid people in place to push this therapy forward. Some of the moves are starting to pay off as CELZ is starting to see a boost in price.
Holding a market cap of $11.23M with a float of 151.04M, CELZ has more than doubled their market cap since we last wrote about them, which is indicative of where this stock might be heading. Keep in mind, the company is seeing recent declines on the top-line on a sequential quarterly basis, with revenues falling at 0% as of its latest reporting period. You can bet we will update this one again as new information comes into view. Sign-up for continuing coverage on shares of $CELZ stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in $CELZ, either long or short, and we have not been compensated for this article.
By Gene Daniel - April 30, 2018
SHARE Facebook Twitter
Creative Medical Technology Holdings Inc (OTCMKTS:CELZ) continues a resurgence that has seen it jump up over +160% over the last month. In addition, CELZ has seen 10-day volume average 91.46M, so investor interest is very strong here. The recent shareholder update has added some upward action to this price increase. One important point that seemed to interest investors was the paying down of debt. This is not anything new as CELZ has been working to tighten up this aspect of the company while letting their technology get further down the pipeline.
“We continue to focus on the business at hand and our portfolio including issued patents for the treatment of erectile dysfunction, degenerative disc disease and our amniotic derived stem cell as well as patents pending in the area of neurological damage due to radiation toxicity and stroke amongst others,” said Timothy Warbington, CEO of CELZ.
Creative Medical Technology Holdings Inc (OTCMKTS:CELZ) bills itself as a company that is engaged in stem cell research and applications for use to treat male and female sexual dysfunction, infertility and related issues. It holds a patent for its erectile dysfunction (“ED”) treatment and was granted a license by Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, a non-profit biomedical research and education institute (“LABIOMED”), for the infertility treatment.
It has also filed a patent application focused on physical manifestations of female sexual arousal disorder, as an extension of the work with stem cell therapies for ED. Following testing of its ED treatment, Creative Medical intends to market treatment kits to physicians for use with their patients suffering from ED. During first quarter 2016, it commenced a 15-month clinical trial study being conducted at UCLA by LABIOMED on the efficacy and safety of the ED treatment.
The study involves testing on 40 subjects. Following further testing, Creative Medical also intends to market licensed products under its infertility technology license and the female sexual dysfunction patent application.
According to company materials, “Creative Medical Technology Holdings, Inc. is a clinical-stage biotechnology company currently trading on the OTCQB under the ticker symbol CELZ.”
Find out when $CELZ stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
Speaking of CELZ’s technology, let’s take a look at that more closely. CELZ’s CaverStem procedure is seeing an opportunity in the urology market for a subset of the male population that does not react to Viagra or Cialis. This subset is not small – 30 million men are resistant to the two well known erectile dysfunction options.
Furthermore, the company has a new subsidiary called CerebroStemLLC working to treat brain injuries through stem cell therapy through their product AmnioStem. “We are extremely excited about our data, which positions Creative Medical Technology Holdings as a force in the autoimmune market. In addition to treatment of stroke and radiation toxicity, autoimmune diseases that may benefit from use of AmnioStem™ technology include Type 1 Diabetes, Rheumatoid Arthritis, Multiple Sclerosis, and Lupus,” said Timothy Warbington, President and Chief Executive Officer of Creative Medical Technology Holdings. “I am thankful for our collaborative network of scientists, scientific advisors, and intellectual property advisors, which are currently working in expanding the intellectual property portfolio surrounding this new cell type.”
CELZ has put solid people in place to push this therapy forward. Some of the moves are starting to pay off as CELZ is starting to see a boost in price.
Holding a market cap of $11.23M with a float of 151.04M, CELZ has more than doubled their market cap since we last wrote about them, which is indicative of where this stock might be heading. Keep in mind, the company is seeing recent declines on the top-line on a sequential quarterly basis, with revenues falling at 0% as of its latest reporting period. You can bet we will update this one again as new information comes into view. Sign-up for continuing coverage on shares of $CELZ stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in $CELZ, either long or short, and we have not been compensated for this article.
(0)
(0)Creative Medical Technology Holdings Inc (CELZ) Stock Research Links
Louis Pasteur -- chance favours only the prepared mind.
Lecture, University of Lille (7 December 1854)
Lecture, University of Lille (7 December 1854)